Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00861614 · ClinicalTrials.gov registry record · Phase 3
Study of Immunotherapy to Treat Advanced Prostate Cancer
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 988
- Enrollment target
NCT00861614: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00861614 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 988 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00861614, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 988 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if advanced prostate cancer patients that are treated with radiotherapy (RT) plus ipilimumab live longer that those treated with RT alone
Primary Outcome
OS is defined as the time in months from randomization date to date of death due to any cause in all randomized subjects. For participants alive at the time of the database cutoff date, OS was censored at the last date the participant was known to be alive.
Interventions
- DRUG Placebo
- DRUG Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 988 participants |
| Start Date | 2009-05 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
What the finished NCT00861614 record still lists
NCT00861614 is an interventional study that assigns participants to a tested intervention. The registered 988 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00861614 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00861614 about?
NCT00861614 is a clinical study titled "Study of Immunotherapy to Treat Advanced Prostate Cancer". The purpose of the study is to determine if advanced prostate cancer patients that are treated with radiotherapy (RT) plus ipilimumab live longer that those treated with RT alone
What is the current status of trial NCT00861614?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 988 participants. The study started on 2009-05. Estimated completion is 2015-08.
What interventions are being tested in trial NCT00861614?
The interventions under investigation include: Placebo (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT00861614?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00861614's enrollment target sits among peer trials
988 320th of 2000 higher than 1,681 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05079841 · 988 participants · Phase 4
The Stimulation To Induce Mothers Study
- NCT05441709 · 990 participants · NA
Furthering Equity Through Infant Feeding EDucation and Support
- NCT06340646 · 990 participants · NA
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
- NCT06878261 · 990 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia